Abstract
Spinal cord injury (SCI) induces dynamic changes of the blood-spinal cord barrier and even the more distant blood-brain barrier. Besides an immediate increase of paracellular permeability resulting from the direct impact of the injury, the transport systems for selective cytokines undergo regulatory changes. Since many of the transported molecules play essential roles in neuroregeneration, we propose that this altered peripheral tissue / CNS interaction benefits remodeling of the spinal cord and functional recovery after SCI. This review examines the transport of cytokines and neurotrophic factors into the spinal cord, emphasizing the upregulation of two cytokines – tumor necrosis factor α (TNF) and leukemia inhibitory factor (LIF) - during the course of SCI. The increased transport of TNF and LIF after SCI remains saturable and does not coincide with generalized BBB disruption, highlighting a pivotal regulatory role for the bloodspinal cord barrier.
Keywords: Spinal cord injury, blood-brain barrier, cytokines, neurotrophins, TNF, LIF
Current Pharmaceutical Design
Title: Cytokine Transport Across the Injured Blood-Spinal Cord Barrier
Volume: 14 Issue: 16
Author(s): Weihong Pan and Abba J. Kastin
Affiliation:
Keywords: Spinal cord injury, blood-brain barrier, cytokines, neurotrophins, TNF, LIF
Abstract: Spinal cord injury (SCI) induces dynamic changes of the blood-spinal cord barrier and even the more distant blood-brain barrier. Besides an immediate increase of paracellular permeability resulting from the direct impact of the injury, the transport systems for selective cytokines undergo regulatory changes. Since many of the transported molecules play essential roles in neuroregeneration, we propose that this altered peripheral tissue / CNS interaction benefits remodeling of the spinal cord and functional recovery after SCI. This review examines the transport of cytokines and neurotrophic factors into the spinal cord, emphasizing the upregulation of two cytokines – tumor necrosis factor α (TNF) and leukemia inhibitory factor (LIF) - during the course of SCI. The increased transport of TNF and LIF after SCI remains saturable and does not coincide with generalized BBB disruption, highlighting a pivotal regulatory role for the bloodspinal cord barrier.
Export Options
About this article
Cite this article as:
Pan Weihong and Kastin J. Abba, Cytokine Transport Across the Injured Blood-Spinal Cord Barrier, Current Pharmaceutical Design 2008; 14 (16) . https://dx.doi.org/10.2174/138161208784705450
DOI https://dx.doi.org/10.2174/138161208784705450 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
Current Medicinal Chemistry The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Mollusk-Derived Growth Factor and the New Subfamily of Adenosine Deaminase-related Growth Factors
Current Pharmaceutical Design Functional Roles of Synaptic and Extrasynaptic NMDA Receptors in Physiological and Pathological Neuronal Activities
Current Drug Targets Integral Therapeutic Potential of Bone Marrow Mesenchymal Stem Cells
Current Drug Targets New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Neurogenic Drugs and Compounds
Recent Patents on CNS Drug Discovery (Discontinued) Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) Biomimetic Synthetic Self-Assembled Hydrogels for Cell Transplantation
Current Topics in Medicinal Chemistry Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology